Warning: The NCBI web site requires JavaScript to function. more...
Prospective strategies to delay the evolution of anti-malarial drug resistance: weighing the uncertainty.
Smith DL, Klein EY, McKenzie FE, Laxminarayan R.
Malar J. 2010 Jul 23;9:217.
Related citations
Spread of anti-malarial drug resistance: mathematical model with implications for ACT drug policies.
Pongtavornpinyo W, Yeung S, Hastings IM, Dondorp AM, Day NP, White NJ.
Malar J. 2008 Nov 2;7:229.
[Combined antimalarial therapy using artemisinin].
Majori G.
Parassitologia. 2004 Jun;46(1-2):85-7. Review. Italian.
Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance.
White NJ, Pongtavornpinyo W, Maude RJ, Saralamba S, Aguas R, Stepniewska K, Lee SJ, Dondorp AM, White LJ, Day NP.
Malar J. 2009 Nov 11;8:253.
Pattern of drug utilization for treatment of uncomplicated malaria in urban Ghana following national treatment policy change to artemisinin-combination therapy.
Dodoo AN, Fogg C, Asiimwe A, Nartey ET, Kodua A, Tenkorang O, Ofori-Adjei D.
Malar J. 2009 Jan 5;8:2.
Epidemiological models for the spread of anti-malarial resistance.
Koella JC, Antia R.
Malar J. 2003 Feb 19;2:3. Epub 2003 Feb 19.
Will a global subsidy of new antimalarials delay the emergence of resistance and save lives?
Laxminarayan R, Over M, Smith DL.
Health Aff (Millwood). 2006 Mar-Apr;25(2):325-36.
Drug resistance hampers our capacity to roll back malaria.
Olliaro P.
Clin Infect Dis. 2005 Aug 15;41 Suppl 4:S247-57. Review.
Monitoring for Plasmodium falciparum drug resistance to artemisinin and artesunate in Binh Phuoc Province, Vietnam: 1998-2009.
Thanh NV, Toan TQ, Cowman AF, Casey GJ, Phuc BQ, Tien NT, Hung NM, Biggs BA.
Malar J. 2010 Jun 24;9:181.
Plasmodium sensitivity to artemisinins: magic bullets hit elusive targets.
Ding XC, Beck HP, Raso G.
Trends Parasitol. 2011 Feb;27(2):73-81. Epub 2010 Dec 18. Review.
Artemisinin-based combination therapies (ACTs): best hope for malaria treatment but inaccessible to the needy!
Mutabingwa TK.
Acta Trop. 2005 Sep;95(3):305-15. Review.
How artemisinin-containing combination therapies slow the spread of antimalarial drug resistance.
Hastings I.
Trends Parasitol. 2011 Feb;27(2):67-72.
Population biology and antimalarial resistance: The transmission of antimalarial drug resistance in Plasmodium falciparum.
Barnes KI, White NJ.
Acta Trop. 2005 Jun;94(3):230-40. Review.
The detection and treatment of Plasmodium falciparum malaria: time for change.
Nosten F, Ashley E.
J Postgrad Med. 2004 Jan-Mar;50(1):35-9.
Malaria. Signs of drug resistance rattle experts, trigger bold plan.
Enserink M.
Science. 2008 Dec 19;322(5909):1776. No abstract available.
Drug resistance models for malaria.
Mackinnon MJ.
Acta Trop. 2005 Jun;94(3):207-17. Review.
Modelling the impact of intermittent preventive treatment for malaria on selection pressure for drug resistance.
Alexander N, Sutherland C, Roper C, Cissé B, Schellenberg D.
Malar J. 2007 Jan 22;6:9.
Clinical pharmacology of artemisinin-based combination therapies.
German PI, Aweeka FT.
Clin Pharmacokinet. 2008;47(2):91-102. Review. Erratum in: Clin Pharmacokinet. 2008;47(3):152.
Drug resistance among malaria and other parasites.
Barat LM, Bloland PB.
Infect Dis Clin North Am. 1997 Dec;11(4):969-87. Review.
Monitoring and deterring drug-resistant malaria in the era of combination therapy.
Laufer MK, Djimdé AA, Plowe CV.
Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):160-9. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on